RED TERAV - Investigadores

Investigadores

Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Inmunoterapia Celular (células CAR)

Investigadores
Publicaciones

Francesc Bosch Albareda

Investigador principal

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Jordi BARQUINERO MÁÑEZ

Investigador principal

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Maria Pallarès Masmitjà

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

PERE BARBA SUÑOL

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

ROCIO PIÑERA MORENO

Investigador colaborador

Grupo de Investigación: Instituto de Investigación Universitario Valle de Hebron (VHIR). Barcelona.

Chong E.A., Penuel E., Napier E.B., Lundberg R.K., Budde L.E., Shadman M., Matasar M.J., Bartlett N.L., Flinn I.W., Bosch F., Fay K., Goy A., Kumar A., Nastoupil L.J., Wei M.C., Wu M., Yin S., Fraietta J.A., Chong E.R., Schuster S.J.. Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Advances. 25 February 2025. DOI: 10.1182/bloodadvances.2024013640.

Impacto: 7.4. Cuartil: Q1

Thorvaldsdottir B., Mansouri L., Sutton L.A., Nadeu F., Meggendorfer M., Parker H., Brieghel C., Laidou S., Moia R., Rossi D., Kotaskova J., Delgado J., Rodríguez-Vicente A.E., Benito R., Rigolin G.M., Bonfiglio S., Scarfò L., Mattsson M., Davis Z., Baliakas P., Rapado I., Miras F., Martinez-Lopez J., de la Serna J., Hernández Rivas J.M., Larráyoz M.J., Calasanz M.J., Smedby K.E., Espinet B., Puiggros A., Bullinger L., Bosch F., Tazón-Vega B., Baran-Marszak F., Oscier D., Nguyen-Khac F., Zenz T., Terol M.J., Cuneo A., Hernández-Sánchez M., Pospisilova S., Gaidano G., Niemann C.U., Campo E., Strefford J.C., Ghia P., Stamatopoulos K., Rosenquist R.. ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA. Leukemia. 2025. DOI: 10.1038/s41375-025-02615-5.

Impacto: 12.8. Cuartil: Q1 (1er decil)

Río P., Zubicaray J., Navarro S., Gálvez E., Sánchez-Domínguez R., Nicoletti E., Sebastián E., Rothe M., Pujol R., Bogliolo M., John-Neek P., Bastone A.L., Schambach A., Wang W., Schmidt M., Larcher L., Segovia J.C., Yáñez R.M., Alberquilla O., Díez B., Fernández-García M., García-García L., Ramírez M., Galy A., Lefrere F., Cavazzana M., Leblanc T., García de Andoin N., López-Almaraz R., Catalá A., Barquinero J., Rodríguez-Perales S., Rao G., Surrallés J., Soulier J., Díaz-de-Heredia C., Schwartz J.D., Sevilla J., Bueren J.A.. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. The Lancet. 21 December 2024. DOI: 10.1016/S0140-6736(24)01880-4.

Impacto: 98.4. Cuartil: Q1 (1er decil)

Smeets H., Verbrugge B., Bulbena X., Hristova L., Vogt J., van Beckhoven I., Allamand V., Almekinders J., Barquinero J., Berreur S., Bönnemann C., Bouman K., de Bruin L., Caron L., Damon C., Durbeej M., Feijen D., Foley R., Goncalves A.R., Camelo C.G., Güell M., Haliloğlu G., Kemaladewi D., Klein A., Koleda N., Minko O., Munell F., Nebermann T., Pini V., Previtali S., Roos A., Rüegg M., Sarkozy A., Seferian A., Stepniewski J., van Straten E., van Tienen F., Quijano-Roy S., Voermans N., West A., Yurchenco P., Moy J., Almeida C., Becker J., Gill L.. European Joint Programme on Rare Diseases workshop: LAMA2-muscular dystrophy: paving the road to therapy March 17–19, 2023, Barcelona, Spain. Neuromuscular Disorders. March 2024. DOI: 10.1016/j.nmd.2024.01.001.

Impacto: 2.7. Cuartil: Q2

Cuenca S., Soler Z., Serrano-Gómez G., Xie Z., Barquinero J., Roca J., Sirvent J.M., Manichanh C.. Dysbiosis: An Indicator of COVID-19 Severity in Critically Ill Patients. International Journal of Molecular Sciences. December 2022. DOI: 10.3390/ijms232415808.

Impacto: 5.6. Cuartil: Q1

Galiñanes M., Casós K., Blasco-Lucas A., Permanyer E., Máñez R., Le Tourneau T., Barquinero J., Schwartz S., Bottio T., Roussel J.C., Fellah-Hebia I., Sénage T., Evangelista A., Badano L.P., Ruiz-Majoral A., Galli C., Padler-Karavani V., Soulillou J.P., Vidal X., Cozzi E., Costa C.. Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study. Biomolecules. November 2022. DOI: 10.3390/biom12111606.

Impacto: 5.5. Cuartil: Q1

Piñana J.L., Vázquez L., Martino R., de la Cámara R., Sureda A., Rodríguez-Veiga R., Garrido A., Sierra J., Ribera J.M., Torrent A., Mateos M.V., de la Rubia J., Tormo M., Díez-Campelo M., García-Gutiérrez V., Álvarez-Larrán A., Sancho J.M., MartínGarcía-Sancho A., Yañez L., Pérez Simón J.A., Barba P., Abrisqueta P., Álvarez-Twose I., Bonanad S., Lecumberri R., Ruiz-Camps I., Navarro D., Hernández-Rivas J.Á., Cedillo Á., García-Sanz R., Bosch F.. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. Leukemia and Lymphoma. 2022. DOI: 10.1080/10428194.2021.1992619.

Impacto: 2.6. Cuartil: Q3

Ribeiro M.L., Reyes-Garau D., Vinyoles M., Pelejà N.P., Santos J.C., Armengol M., Fernández-Serrano M., Mor A.S., Bech-Serra J.J., Blecua P., Musulen E., de la Torre C., Miskin H., Esteller M., Bosch F., Menéndez P., Normant E., Roué G.. Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of ikaros signaling in patients with B-cell non–hodgkin lymphoma. Clinical Cancer Research. 1 December 2021. DOI: 10.1158/1078-0432.CCR-21-1067.

Impacto: 13.801. Cuartil: Q1 (1er decil)

Villacampa G., Dienstmann R., Bosch F., Abrisqueta P.. Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.. Annals of Hematology. December 2021. DOI: 10.1007/s00277-021-04623-8.

Impacto: 4.03. Cuartil: Q2

Pallarès-Masmitjà M., Ivančić D., Mir-Pedrol J., Jaraba-Wallace J., Tagliani T., Oliva B., Rahmeh A., Sánchez-Mejías A., Güell M.. Find and cut-and-transfer (FiCAT) mammalian genome engineering. Nature Communications. December 2021. DOI: 10.1038/s41467-021-27183-x.

Impacto: 17.694. Cuartil: Q1 (1er decil)

Jiménez I., Tazón-Vega B., Abrisqueta P., Nieto J.C., Bobillo S., Palacio-García C., Carabia J., Valdés-Mas R., Munuera M., Puigdefàbregas L., Parra G., Esteve-Codina A., Franco-Jarava C., Iacoboni G., Terol M.J., García-Marco J.A., Crespo M., Bosch F.. Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomarker Research. December 2021. DOI: 10.1186/s40364-021-00290-z.

Impacto: 8.633. Cuartil: Q1

Parés M., Fornaguera C., Vila-Julià F., Oh S., Fan S.H.Y., Tam Y.K., Comes N., Vidal F., Martí R., Borrós S., Barquinero J.. Preclinical Assessment of a Gene-Editing Approach in a Mouse Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. Human Gene Therapy. October 2021. DOI: 10.1089/hum.2021.152.

Impacto: 4.793. Cuartil: Q1

Dlouhy I., Armengol M., Recasens-Zorzo C., Ribeiro M.L., Pérez-Galán P., Bosch F., López-Guillermo A., Roué G.. Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation. Haematologica. October 2021. DOI: 10.3324/haematol.2020.278258.

Impacto: 11.047. Cuartil: Q1 (1er decil)

Puiggros A., Blanco G., Muntasell A., Rodríguez-Rivera M., Nonell L., Altadill M., Puigdecanet E., Arnal M., Calvo X., Gimeno E., Abella E., Abrisqueta P., Bosch F., Yélamos J., Ferrer A., López-Botet M., Espinet B.. Reduced expansion of CD94/NKG2C+ NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or NKG2C deletions. International Journal of Laboratory Hematology. October 2021. DOI: 10.1111/ijlh.13494.

Impacto: 3.45. Cuartil: Q3

Iacoboni G., Simó M., Villacampa G., Catalá E., Carpio C., Díaz-Lagares C., Vidal-Jordana Á., Bobillo S., Marín-Niebla A., Pérez A., Jiménez M., Abrisqueta P., Bosch F., Barba P.. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Annals of Hematology. September 2021. DOI: 10.1007/s00277-021-04560-6.

Impacto: 4.03. Cuartil: Q2

Bosch F., Dalla-Favera R.. Genetics of Chronic Lymphocytic Leukemia. Cancer Journal (United States). 2021. DOI: 10.1097/PPO.0000000000000538.

Impacto: 2.074. Cuartil: Q4

Stilgenbauer S., Bosch F., Ilhan O., Kisro J., Mahé B., Mikuskova E., Osmanov D., Reda G., Robinson S., Tausch E., Turgut M., Wójtowicz M., Böttcher S., Perretti T., Trask P., Van Hoef M., Leblond V., Foà R.. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British Journal of Haematology. April 2021. DOI: 10.1111/bjh.17326.

Impacto: 8.615. Cuartil: Q1

Blanco G., Puiggros A., Sherry B., Nonell L., Calvo X., Puigdecanet E., Chiu P.Y., Kieso Y., Ferrer G., Palacios F., Arnal M., Rodríguez-Rivera M., Gimeno E., Abella E., Rai K.R., Abrisqueta P., Bosch F., Calon A., Ferrer A., Chiorazzi N., Espinet B.. Chronic lymphocytic leukemia–like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. Experimental Hematology. March 2021. DOI: 10.1016/j.exphem.2020.12.007.

Impacto: 3.249. Cuartil: Q3

Bosch F., Navarro B., Crespo M., Alcoceba M., Sánchez J.B., Tazón B., Serrano A., Álvarez M.G., Serrano L.G., Alonso-Torres P., Villanueva M., Loriente C., Abrisqueta P., Peiró M., García-Marco J.A., González M., Terol M.J.. Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. Annals of Hematology. March 2021. DOI: 10.1007/s00277-020-04331-9.

Impacto: 4.03. Cuartil: Q2

Bobillo S., Crespo M., Escudero L., Mayor R., Raheja P., Carpio C., Rubio-Perez C., Tazón-Vega B., Palacio C., Carabia J., Jiménez I., Juan C.N., Montoro J., Martínez-Ricarte F., Castellví J., Simó M., Puigdefàbregas L., Abrisqueta P., Bosch F., Seoane J.. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. February 2021. DOI: 10.3324/haematol.2019.241208.

Impacto: 11.047. Cuartil: Q1 (1er decil)

Carpio C., Iacoboni G., Villacampa G., Catalá E., Bobillo S., Pérez A., Jiménez M., Segura L., Olivé M., Farriols A., Abrisqueta P., Valcárcel D., Carreras M.J., Bosch F., Barba P.. Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. Leukemia and Lymphoma. 2021. DOI: 10.1080/10428194.2021.1913141.

Impacto: 2.996. Cuartil: Q3

Hidalgo-Gómez G., Palacio-Garcia C., Gallur L., Blanco A., Tazón-Vega B., Saumell S., Martínez N., Murillo L., Murciano T., Velasco P., Bosch F., Diaz-Heredia C., Ortega M.. Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis. Leukemia and Lymphoma. 2021. DOI: 10.1080/10428194.2021.1907375.

Impacto: 2.996. Cuartil: Q3

Salamero O., Montesinos P., Willekens C., Pérez-Simón J.A., Pigneux A., Récher C., Popat R., Carpio C., Molinero C., Mascaró C., Vila J., Isabel Arévalo M., Maes T., Buesa C., Bosch F., Somervaille T.C.P.. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 20 December 2020. DOI: 10.1200/JCO.19.03250.

Impacto: 44.544. Cuartil: Q1 (1er decil)

Nieto J.C., Roldán E., Jiménez I., Fox L., Carabia J., Ortí G., Puigdefàbregas L., Gallur L., Iacoboni G., Raheja P., Pérez A., Bobillo S., Salamero O., Palacio C., Valcárcel D., Crespo M., Bosch F., Barba P.. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. December 2020. DOI: 10.1038/s41375-020-0851-8.

Impacto: 11.528. Cuartil: Q1 (1er decil)

Riveiro-Barciela M., Gubern P., Roade L., Abrisqueta P., Carreras M.J., Farriols A., Bosch F., Esteban R., Buti M.. An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. Scientific Reports. 1 December 2020. DOI: 10.1038/s41598-020-59476-4.

Impacto: 4.379. Cuartil: Q1

Muntañola A., Villacampa G., Hernández-Rivas J.Á., Alonso R., Mirás F., Osorio S., Baile M., Baltasar P., López Jiménez J., Hernandez-Rodriguez I., Valenciano S., Alfayate A., Gimeno E., Bárez A., Oliveira A.C., Riaza R., Romero P., Delgado J., Yáñez L., Zabalza A., Torres A., Gómez-Roncero M.ª., Crespo M., Córdoba R., Mateos-Mazón J.J., Pérez S., Andreu R., Labrador J., Ruiz M.ª., Velasquez C.A., Terol M.ª., Santiago R., Vidal M.ª., Campoy García F., Villalón L., Muiña B.S., Soler J.A., Seri C., Sánchez M.ª., Cuesta A., Ramos R., Sánchez-Montalvá A., Ruiz-Camps I., González M., Abrisqueta P., Bosch F.. Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Experimental Hematology and Oncology. December 2020. DOI: 10.1186/s40164-020-00195-x.

Abrisqueta P., Delgado J., Alcoceba M., Oliveira A.C., Loscertales J., Hernández-Rivas J.A., Ferrà C., Cordoba R., Yáñez L., Medina A., Motlló C., Iacoboni G., Villacampa G., González M., Bosch F.. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). British Journal of Haematology. 1 September 2020. DOI: 10.1111/bjh.16748.

Impacto: 6.998. Cuartil: Q1

Jiménez I., Carabia J., Bobillo S., Palacio C., Abrisqueta P., Pagès C., Nieto J.C., Castellví J., Martínez-Ricarte F., Escoda L., Perla C., Céspedes Torrez D.H., Boix J., Purroy N., Puigdefàbregas L., Seoane J., Bosch F., Crespo M.. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. Journal of Neuro-Oncology. 1 August 2020. DOI: 10.1007/s11060-020-03580-y.

Impacto: 4.13. Cuartil: Q2

González-Gascón-y-Marín I., Muñoz-Novas C., Figueroa I., Hernández-Sánchez M., Rodríguez-Vicente A.E., Quijada-Álamo M., Pérez-Carretero C., Moreno C., Collado R., Espinet B., Puiggros A., Heras N.d.l., Bosch F., Hernández J.Á.. Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. Clinical Lymphoma, Myeloma and Leukemia. August 2020. DOI: 10.1016/j.clml.2020.03.003.

Impacto: 3.231. Cuartil: Q3

Gordon L.I., Kaplan J.B., Popat R., Burris H.A., Ferrari S., Madan S., Patel M.R., Gritti G., El-Sharkawi D., Chau I., Radford J.A., de Oteyza J.P., Zinzani P.L., Iyer S., Townsend W., Karmali R., Miao H., Proscurshim I., Wang S., Wu Y., Stumpo K., Shou Y., Carpio C., Bosch F.. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C. Clinical Cancer Research. 15 July 2020. DOI: 10.1158/1078-0432.CCR-19-3239.

Impacto: 12.531. Cuartil: Q1 (1er decil)

Fumanal M., Di Zeo D.E., Anguís V., Fernández-Diaz C., Alarcón F.J., Piñera R., Albaladejo-Riad N., Esteban M.A., Moriñigo M.A., Balebona M.C.. Inclusion of dietary Ulva ohnoi 5% modulates Solea senegalensis immune response during Photobacterium damselae subsp. piscicida infection. Fish and Shellfish Immunology. May 2020. DOI: 10.1016/j.fsi.2020.03.007.

Impacto: 4.581. Cuartil: Q1 (1er decil)

Abrisqueta P., Bosch F.. Venetoclax-obinutuzumab: harnessing complexity. Blood. March 2020. DOI: 10.1182/BLOOD.2019004463.

Impacto: 22.113. Cuartil: Q1 (1er decil)

Bosch F., Cantin G., Cortelezzi A., Knauf W., Tiab M., Turgut M., Zaritskey A., Merot J.L., Tausch E., Trunzer K., Robson S., Gresko E., Böttcher S., Foà R., Stilgenbauer S., Leblond V.. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 1 February 2020. DOI: 10.1038/s41375-019-0554-1.

Impacto: 11.528. Cuartil: Q1 (1er decil)

Martorell L., Cortina V., Parra R., Barquinero J., Vidal F.. Variable readthrough responsiveness of nonsense mutations in hemophilia A. Haematologica. 31 January 2020. DOI: 10.3324/haematol.2018.212118.

Impacto: 9.941. Cuartil: Q1 (1er decil)

Fox M.L., García-Cadenas I., Pérez A.M., Villacampa G., Piñana J.L., Ortí G., Montoro J., Roldán E., Bosch Vilaseca A., Martino R., Salamero O., Saavedra S., Hernandez-Boluda J.C., Esquirol A., Sierra J., Sanz J., Solano C., Bosch F., Barba P., Valcarcel D.. Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia and Lymphoma. 2020. DOI: 10.1080/10428194.2020.1788015.

Impacto: 3.28. Cuartil: Q3

Tarrasó G., Real-Martinez A., Parés M., Romero-Cortadellas L., Puigros L., Moya L., Luna N., Brull A., Martín M.A., Arenas J., Lucia A., Andreu A.L., Barquinero J., Vissing J., Krag T.O., Pinós T.. Absence of p.R50X Pygm read-through in McArdle disease cellular models. DMM Disease Models and Mechanisms. 2020. DOI: 10.1242/dmm.043281.

Impacto: 5.758. Cuartil: Q1

Bosch F., Dalla-Favera R.. Chronic lymphocytic leukaemia: from genetics to treatment. Nature Reviews Clinical Oncology. 1 November 2019. DOI: 10.1038/s41571-019-0239-8.

Impacto: 53.276. Cuartil: Q1 (1er decil)

Río P., Navarro S., Wang W., Sánchez-Domínguez R., Pujol R.M., Segovia J.C., Bogliolo M., Merino E., Wu N., Salgado R., Lamana M.L., Yañez R.M., Casado J.A., Giménez Y., Román-Rodríguez F.J., Álvarez L., Alberquilla O., Raimbault A., Guenechea G., Lozano M.L., Cerrato L., Hernando M., Gálvez E., Hladun R., Giralt I., Barquinero J., Galy A., García de Andoín N., López R., Catalá A., Schwartz J.D., Surrallés J., Soulier J., Schmidt M., Díaz de Heredia C., Sevilla J., Bueren J.A.. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nature Medicine. 1 September 2019. DOI: 10.1038/s41591-019-0550-z.

Impacto: 36.13. Cuartil: Q1 (1er decil)

Scuoppo C., Wang J., Persaud M., Mittan S.K., Basso K., Pasqualucci L., Rabadan R., Inghirami G., Grandori C., Bosch F., Dalla-Favera R.. Repurposing dasatinib for diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 20 August 2019. DOI: 10.1073/pnas.1905239116.

Impacto: 9.412. Cuartil: Q1

Pardos-Gea J., Martínez F., Abrisqueta P., Santamaría A., Bosch F.. Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjögren's syndrome: Which associated condition should be prioritized?. Blood Coagulation and Fibrinolysis. 1 July 2019. DOI: 10.1097/MBC.0000000000000814.

Impacto: 1.203. Cuartil: Q4

Montoro J., Pomares H., Villacampa G., Merchán B., Molero A., Alonso E., Gallur L., Grau J., Salamero O., Roldán E., Saumell S., Ortega M., Sureda A., Bosch F., Arnan M., Valcárcel D.. Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. Leukemia and Lymphoma. 12 May 2019. DOI: 10.1080/10428194.2018.1542151.

Impacto: 2.969. Cuartil: Q2

Ortí G., Iacoboni G., Barba P., Gimeno R., Roldán E., Fox L., Salamero O., Bosch F., Valcárcel D.. Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report. Bone Marrow Transplantation. 1 May 2019. DOI: 10.1038/s41409-018-0402-3.

Impacto: 4.725. Cuartil: Q1

Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu B., Nagler A., Ozcan M., Avivi I., Bosch F., Caballero Barrigón M.D., Hellmann A., Kuss B., Ma D.D.F., Demirkan F., Yağci M., Horowitz N.A., Marlton P., Cordoba R., Wrobel T., Buglio D., Streit M., Hodkinson B.P., Schaffer M., Alvarez J., Ceulemans R., Balasubramanian S., de Jong J., Wang S.S., Fourneau N., Jurczak W.. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. The Lancet Haematology. February 2019. DOI: 10.1016/S2352-3026(18)30217-5.

Impacto: 10.406. Cuartil: Q1 (1er decil)

Pallarès Masmitjà M., Knödlseder N., Güell M.. CRISPR-gRNA Design. Methods in Molecular Biology. 2019. DOI: 10.1007/978-1-4939-9170-9_1.

Flinn I.W., Hillmen P., Montillo M., Nagy Z., Illés Á., Etienne G., Delgado J., Kuss B.J., Tam C.S., Gasztonyi Z., Offner F., Lunin S., Bosch F., Davids M.S., Lamanna N., Jaeger U., Ghia P., Cymbalista F., Portell C.A., Skarbnik A.P., Cashen A.F., Weaver D.T., Kelly V.M., Turnbull B., Stilgenbauer S.. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 6 December 2018. DOI: 10.1182/blood-2018-05-850461.

Impacto: 16.562. Cuartil: Q1 (1er decil)

Bobillo S., Abrisqueta P., Sánchez-González B., Giné E., Romero S., Alcoceba M., González-Barca E., González de Villambrosía S., Sancho J.M., Gómez P., Bento L., Montoro J., Montes S., López A., Bosch F.. Posttransplant monomorphic Burkitt’s lymphoma: clinical characteristics and outcome of a multicenter series. Annals of Hematology. 1 December 2018. DOI: 10.1007/s00277-018-3473-8.

Impacto: 2.85. Cuartil: Q3

Leblond V., Aktan M., Coll C.M.F., Dartigeas C., Kisro J., Montillo M., Raposo J., Merot J.L., Robson S., Gresko E., Bosch F., Stilgenbauer S., Foà R.. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb green study. Haematologica. 31 October 2018. DOI: 10.3324/haematol.2017.186387.

Impacto: 7.57. Cuartil: Q1 (1er decil)

Yeung C.C.S., Hockenbery D.M., Westerhoff M., Coutre S.E., Sedlak R.H., Dubowy R.L., Munugalavadla V., Taylor K., Bosch F.. Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. Future Oncology. September 2018. DOI: 10.2217/fon-2017-0528.

Impacto: 2.279. Cuartil: Q3

Stilgenbauer S., Leblond V., Foà R., Böttcher S., Ilhan O., Knauf W., Mikuskova E., Renner C., Tausch E., Woszczyk D., Gresko E., Lundberg L., Moore T., Morris T., Robson S., Bosch F.. Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 1 August 2018. DOI: 10.1038/s41375-018-0146-5.

Impacto: 9.944. Cuartil: Q1 (1er decil)

Montoro J., Gallur L., Merchán B., Molero A., Roldán E., Martínez-Valle F., Villacampa G., Navarrete M., Ortega M., Castellví J., Saumell S., Bobillo S., Bosch F., Valcárcel D.. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. Annals of Hematology. 1 August 2018. DOI: 10.1007/s00277-018-3302-0.

Impacto: 2.85. Cuartil: Q3

Blaya D., Aguilar-Bravo B., Hao F., Casacuberta-Serra S., Coll M., Perea L., Vallverdú J., Graupera I., Pose E., Llovet L., Barquinero J., Cubero F.J., Caballería J., Ginès P., Sancho-Bru P.. Expression of microRNA-155 in inflammatory cells modulates liver injury. Hepatology. August 2018. DOI: 10.1002/hep.29833.

Impacto: 14.971. Cuartil: Q1 (1er decil)

Blanco G., Vardi A., Puiggros A., Gómez-Llonín A., Muro M., Rodríguez-Rivera M., Stalika E., Abella E., Gimeno E., López-Sánchez M., Senín A., Calvo X., Abrisqueta P., Bosch F., Ferrer A., Stamatopoulos K., Espinet B.. Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. OncoImmunology. 3 June 2018. DOI: 10.1080/2162402X.2018.1432328.

Impacto: 5.333. Cuartil: Q1

Bosch F., Hallek M.. Venetoclax after idelalisib: Relevant progress for CLL. Blood. 12 April 2018. DOI: 10.1182/blood-2018-02-826396.

Impacto: 16.562. Cuartil: Q1 (1er decil)

González-Gascón y Marín I., Hernández-Sanchez M., Rodríguez-Vicente A.E., Puiggros A., Collado R., Luño E., González T., Ruiz-Xivillé N., Ortega M., Gimeno E., Muñoz C., Infante M.S., Delgado J., Vargas M.T., González M., Bosch F., Espinet B., Hernández-Rivas J.M., Hernández J.Á.. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. Leukemia and Lymphoma. 4 March 2018. DOI: 10.1080/10428194.2017.1349901.

Impacto: 2.674. Cuartil: Q3

Gribben J.G., Bosch F., Cymbalista F., Geisler C.H., Ghia P., Hillmen P., Moreno C., Stilgenbauer S.. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British Journal of Haematology. March 2018. DOI: 10.1111/bjh.15080.

Impacto: 5.206. Cuartil: Q1

Bobillo S., Abrisqueta P., Carpio C., Raheja P., Castellví J., Crespo M., Bosch F.. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. Haematologica. 31 January 2018. DOI: 10.3324/haematol.2017.181636.

Impacto: 7.57. Cuartil: Q1 (1er decil)

Caminal M., Vélez R., Rabanal R.M., Vivas D., Batlle-Morera L., Aguirre M., Barquinero J., García J., Vives J.. A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies. Journal of Tissue Engineering and Regenerative Medicine. December 2017. DOI: 10.1002/term.2254.

Impacto: 4.089. Cuartil: Q1

Carabia J., Carpio C., Abrisqueta P., Jiménez I., Purroy N., Calpe E., Palacio C., Bosch F., Crespo M.. Microenvironment regulates the expression of MIR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. Scientific Reports. 1 December 2017. DOI: 10.1038/s41598-017-12135-7.

Impacto: 4.122. Cuartil: Q1

Dornier E., Rabas N., Mitchell L., Novo D., Dhayade S., Marco S., MacKay G., Sumpton D., Pallares M., Nixon C., Blyth K., MacPherson I.R., Rainero E., Norman J.C.. Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications. 1 December 2017. DOI: 10.1038/s41467-017-02101-2.

Impacto: 12.353. Cuartil: Q1 (1er decil)

Martorell L., Luce E., Vazquez J.L., Richaud-Patin Y., Jimenez-Delgado S., Corrales I., Borras N., Casacuberta-Serra S., Weber A., Parra R., Altisent C., Follenzi A., Dubart-Kupperschmitt A., Raya A., Vidal F., Barquinero J.. Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA. Journal of Thrombosis and Haemostasis. November 2017. DOI: 10.1111/jth.13808.

Impacto: 4.899. Cuartil: Q1

Fink A.M., Bahlo J., Robrecht S., Al-Sawaf O., Aldaoud A., Hebart H., Jentsch-Ullrich K., Dörfel S., Fischer K., Wendtner C.M., Nösslinger T., Ghia P., Bosch F., Kater A.P., Döhner H., Kneba M., Kreuzer K.A., Tausch E., Stilgenbauer S., Ritgen M., Böttcher S., Eichhorst B., Hallek M.. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. The Lancet Haematology. October 2017. DOI: 10.1016/S2352-3026(17)30171-0.

Impacto: 10.698. Cuartil: Q1 (1er decil)

Casacuberta-Serra S., Parés M., Golbano A., Coves E., Espejo C., Barquinero J.. Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes. Immunology and Cell Biology. 1 July 2017. DOI: 10.1038/icb.2017.4.

Impacto: 3.795. Cuartil: Q2

García-Marco J.A., Delgado J., Hernández-Rivas J.A., Ramírez Payer Á., Loscertales Pueyo J., Jarque I., Abrisqueta P., Giraldo P., Martínez R., Yáñez L., Terol M.J., González M., Bosch F.. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. Medicina Clinica. 21 April 2017. DOI: 10.1016/j.medcli.2016.12.030.

Impacto: 1.168. Cuartil: Q3

Casós K., Ferrer-Curriu G., Soler-Ferrer P., Pérez M.L., Permanyer E., Blasco-Lucas A., Gracia-Baena J.M., Castro M.A., Sureda C., Barquinero J., Galiñanes M.. Response of the human myocardium to ischemic injury and preconditioning: The role of cardiac and comorbid conditions, medical treatment, and basal redox status. PLoS ONE. April 2017. DOI: 10.1371/journal.pone.0174588.

Impacto: 2.766. Cuartil: Q1

Orti G., Barba P., Fox L., Salamero O., Bosch F., Valcarcel D.. Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. Experimental Hematology. 1 April 2017. DOI: 10.1016/j.exphem.2016.12.004.

Impacto: 2.436. Cuartil: Q3

Puiggros A., Collado R., Calasanz M.J., Ortega M., Ruiz-Xivillé N., Rivas-Delgado A., Luño E., González T., Navarro B., García-Malo M.D., Valiente A., Hernández J.á., Ardanaz M.T., Piñan M.á., Blanco M.L., Hernández-Sánchez M., Batlle-López A., Salgado R., Salido M., Ferrer A., Abrisqueta P., Gimeno E., Abella E., Ferrá C., Terol M.J., Ortuño F., Costa D., Moreno C., Carbonell F., Bosch F., Delgado J., Espinet B.. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Oncotarget. 2017. DOI: 10.18632/oncotarget.17350.

Purroy N., Carabia J., Abrisqueta P., Egia L., Aguiló M., Carpio C., Palacio C., Crespo M., Bosch F.. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget. 2017. DOI: 10.18632/oncotarget.13557.

Casacuberta-Serra S., Costa C., Eixarch H., Mansilla M.J., López-Estévez S., Martorell L., Parés M., Montalban X., Espejo C., Barquinero J.. Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. Experimental Neurology. 1 December 2016. DOI: 10.1016/j.expneurol.2016.09.012.

Impacto: 4.706. Cuartil: Q1

Städler N., Shang A., Bosch F., Briggs A., Goede V., Berthier A., Renaudin C., Leblond V.. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. Advances in Therapy. 1 October 2016. DOI: 10.1007/s12325-016-0398-2.

Impacto: 2.709. Cuartil: Q2

Torres-Torronteras J., Cabrera-Pérez R., Barba I., Costa C., De Luna N., Andreu A.L., Barquinero J., Hirano M., Cámara Y., Martí R.. Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. Human Gene Therapy. 1 September 2016. DOI: 10.1089/hum.2015.160.

Impacto: 4.187. Cuartil: Q1

González-Gascón y Marín I., Hernández-Sánchez M., Rodríguez-Vicente A.E., Sanzo C., Aventín A., Puiggros A., Collado R., Heras C., Muñoz C., Delgado J., Ortega M., González M.T., Marugán I., de la Fuente I., Recio I., Bosch F., Espinet B., González M., Hernández-Rivas J.M., Hernández J.Á.. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematological Oncology. 1 June 2016. DOI: 10.1002/hon.2196.

Impacto: 3.118. Cuartil: Q2

Rawstron A.C., Fazi C., Agathangelidis A., Villamor N., Letestu R., Nomdedeu J., Palacio C., Stehlikova O., Kreuzer K.A., Liptrot S., O'Brien D., De Tute R.M., Marinov I., Hauwel M., Spacek M., Dobber J., Kater A.P., Gambell P., Soosapilla A., Lozanski G., Brachtl G., Lin K., Boysen J., Hanson C., Jorgensen J.L., Stetler-Stevenson M., Yuan C., Broome H.E., Rassenti L., Craig F., Delgado J., Moreno C., Bosch F., Egle A., Doubek M., Pospisilova S., Mulligan S., Westerman D., Sanders C.M., Emerson R., Robins H.S., Kirsch I., Shanafelt T., Pettitt A., Kipps T.J., Wierda W.G., Cymbalista F., Hallek M., Hillmen P., Montserrat E., Ghia P.. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: An European Research Initiative on CLL study. Leukemia. 1 April 2016. DOI: 10.1038/leu.2015.313.

Impacto: 11.702. Cuartil: Q1 (1er decil)

Pons V., Olivera P., García-Consuegra R., López-Andreoni L., Martín-Begué N., García A., Hidalgo J., Bosch F., Santamaría A.. Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. Journal of Thrombosis and Thrombolysis. 1 April 2016. DOI: 10.1007/s11239-015-1225-3.

Impacto: 2.142. Cuartil: Q3

Blanco G., Puiggros A., Baliakas P., Athanasiadou A., García-Malo M.D., Collado R., Xochelli A., Rodríguez-Rivera M., Ortega M., Calasanz M.J., Luño E., Vargas M.T., Grau J., Martínez-Laperche C., Valiente A., Cervera J., Anagnostopoulos A., Gimeno E., Abella E., Stalika E., Hernández-Rivas J.M., Ortuño F.J., Robles D., Ferrer A., Ivars D., González M., Bosch F., Abrisqueta P., Stamatopoulos K., Espinet B.. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016. DOI: 10.18632/oncotarget.13106.

Impacto: 5.168. Cuartil: Q1

Hernández J.Á., Hernández-Sánchez M., Rodríguez-Vicente A.E., Grossmann V., Collado R., Heras C., Puiggros A., Martín A.Á., Puig N., Benito R., Robledo C., Delgado J., González T., Queizán J.A., Galende J., De La Fuente I., Martín-Núñez G., Alonso J.M., Abrisqueta P., Luño E., Marugán I., González-Gascón I., Bosch F., Kohlmann A., González M., Espinet B., Hernández-Rivas J.M.. A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia. PLoS ONE. 1 December 2015. DOI: 10.1371/journal.pone.0143073.

Impacto: 3.057. Cuartil: Q1

Bosch F., Abrisqueta P.. Ibrutinib in CLL: 2 sides of the same coin. Blood. 5 November 2015. DOI: 10.1182/blood-2015-09-670653.

Impacto: 11.847. Cuartil: Q1 (1er decil)

Riveiro-Barciela M., Artaza G., Abrisqueta P., Bosch F., Buti M.. Importance of hepatitis B virus screening in hematological patients. Gastroenterologia y Hepatologia. November 2015. DOI: 10.1016/j.gastrohep.2015.03.004.

Impacto: 0.8. Cuartil: Q4

Cabrera-Pérez R., Torres-Torronteras J., Vila-Julià F., Ortega F.J., Cámara Y., Barquinero J., Martí R.. Prospective therapeutic approaches in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Expert Opinion on Orphan Drugs. 3 October 2015. DOI: 10.1517/21678707.2015.1090307.

Impacto: 0.464. Cuartil: Q4

Martorell L., Corrales I., Ramirez L., Parra R., Raya A., Barquinero J., Vidal F.. Molecular characterization of ten F8 splicing mutations in RNA isolated from patient's leucocytes: Assessment of in silico prediction tools accuracy. Haemophilia. 1 March 2015. DOI: 10.1111/hae.12562.

Impacto: 2.673. Cuartil: Q2

Purroy N., Abrisqueta P., Carabia J., Carpio C., Palacio C., Bosch F., Crespo M.. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015. DOI: 10.18632/oncotarget.2939.

Impacto: 5.008. Cuartil: Q1

Purroy N., Abrisqueta P., Carabia J., Carpio C., Calpe E., Palacio C., Castellví J., Crespo M., Bosch F.. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 1 October 2014. DOI: 10.1038/leu.2014.96.

Impacto: 10.431. Cuartil: Q1 (1er decil)

López-Estévez S., Ferrer G., Torres-Torronteras J., Mansilla M.J., Casacuberta-Serra S., Martorell L., Hirano M., Martí R., Barquinero J.. Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy. Gene Therapy. July 2014. DOI: 10.1038/gt.2014.41.

Impacto: 3.104. Cuartil: Q2

Torres-Torronteras J., Viscomi C., Cabrera-Pérez R., Cámara Y., Di Meo I., Barquinero J., Auricchio A., Pizzorno G., Hirano M., Zeviani M., Martí R.. Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. Molecular Therapy. May 2014. DOI: 10.1038/mt.2014.6.

Impacto: 6.227. Cuartil: Q1 (1er decil)

Gomez A., Espejo C., Eixarch H., Casacuberta-Serra S., Mansilla M.J., Sanchez R., Pereira S., Lopez-Estevez S., Gimeno R., Montalban X., Barquinero J.. Myeloid-derived suppressor cells are generated during retroviral transduction of murine bone marrow. Cell Transplantation. January 2014. DOI: 10.3727/096368912X658971.

Impacto: 3.127. Cuartil: Q2

Baptista M.J., Calpe E., Fernandez E., Colomo L., Cardesa-Salzmann T.M., Abrisqueta P., Bosch F., Crespo M.. Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. Leukemia Research. April 2014. DOI: 10.1016/j.leukres.2014.01.001.

Impacto: 2.351. Cuartil: Q3

Barba P., Martino R., Pérez-Simón J.A., Fernández-Avilés F., Castillo N., Piñana J.L., López-Anglada L., Rovira M., Bosch F., Carreras E., Corral L.L., Sierra J., Valcárcel D.. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. January 2014. DOI: 10.1016/j.bbmt.2013.10.011.

Impacto: 3.404. Cuartil: Q2

Calpe E., Purroy N., Carpio C., Abrisqueta P., Carabia J., Palacio C., Castellví J., Crespo M., Bosch F.. ZAP-70 Promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation. PLoS ONE. 3 December 2013. DOI: 10.1371/journal.pone.0081221.

Impacto: 3.534. Cuartil: Q1

Flix B., Suárez-Calvet X., Díaz-Manera J., Santos-Nogueira E., Mancuso R., Barquinero J., Navas M., Navarro X., Illa I., Gallardo E.. Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement. Stem Cells and Development. 1 November 2013. DOI: 10.1089/scd.2013.0049.

Impacto: 4.202. Cuartil: Q1 (1er decil)

García Marco J.A., Giraldo Castellano P., López Jiménez J., Ríos Herranz E., Sastre Moral J.L., Terol Casterá M.J., Bosch Albareda F.. National guidelines for the management of patients with chronic lymphocytic leukemia. Medicina Clinica. 17 August 2013. DOI: 10.1016/j.medcli.2013.04.041.

Impacto: 1.252. Cuartil: Q3

Mora D., Barba P., Ruiz I., Castillo N., Aizpurua M., Roselló E., Bosch F., Valcárcel D.. Primary gastrointestinal aspergillosis 6 months after allogeneic hematopoietic cell transplantation: A case report. Transplant Infectious Disease. June 2013. DOI: 10.1111/tid.12082.

Impacto: 2.25. Cuartil: Q2

Villamor N., Conde L., Martínez-Trillos A., Cazorla M., Navarro A., Beà S., López C., Colomer D., Pinyol M., Aymerich M., Rozman M., Abrisqueta P., Baumann T., Delgado J., Giné E., González-Díaz M., Hernández J.M., Colado E., Payer A.R., Rayon C., Navarro B., JoséTerol M., Bosch F., Quesada V., Puente X.S., López-Otín C., Jares P., Pereira A., Campo E., López-Guillermo A.. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. May 2013. DOI: 10.1038/leu.2012.357.

Impacto: 9.379. Cuartil: Q1 (1er decil)

Abrisqueta P., Villamor N., Terol M.J., González-Barca E., González M., Ferrà C., Abella E., Delgado J., García-Marco J.A., González Y., Carbonell F., Ferrer S., Monzó E., Jarque I., Muntañola A., Constants M., Escoda L., Calvo X., Bobillo S., Montoro J.B., Montserrat E., Bosch F.. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013. DOI: 10.1182/blood-2013-05-502773.

Puiggros A., Delgado J., Rodriguez-Vicente A., Collado R., Aventín A., Luño E., Grau J., Hernandez J.A., Marugán I., Ardanaz M., González T., Valiente A., Osma M., Calasanz M.J., Sanzo C., Carrió A., Ortega M., Santacruz R., Abrisqueta P., Abella E., Bosch F., Carbonell F., Solé F., Hernández J.M., Espinet B.. Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: Analysis of 627 patients with isolated 13q deletion. British Journal of Haematology. October 2013. DOI: 10.1111/bjh.12479.

Impacto: 4.959. Cuartil: Q1

Barquinero J.. Next-generation scholarly communication: A researcher's perspective. International Microbiology. 2013. DOI: 10.2436/20.1501.01.201.

Impacto: 1.341. Cuartil: Q3

Baptista M.J., Muntanõla A., Calpe E., Abrisqueta P., Salamero O., Fernańdez E., Codony C., Giné E., Kalko S.G., Crespo M., Bosch F.. Differential gene expression profile associated to apoptosis induced by dexamethasone in CLL cells according to IGHV/ZAP-70 status. Clinical Cancer Research. 1 November 2012. DOI: 10.1158/1078-0432.CCR-11-2771.

Impacto: 7.837. Cuartil: Q1 (1er decil)

Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S., Iglesias M., Salido M., Gallen M., Marsters S., Tsai S., Minoche A., Somasekar S., Serrano S., Himmelbauer H., Bellmunt J., Rovira A., Settleman J., Bosch F., Albanell J.. Erratum: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer (Nature Medicine (2012) 18 (221-223)). Nature Medicine. September 2012. DOI: 10.1038/nm0912-1445b.

Impacto: 24.302. Cuartil: Q1 (1er decil)

Wendtner C.M., Hillmen P., Mahadevan D., Bhler A., Uharek L., Coutré S., Frankfurt O., Bloor A., Bosch F., Furman R.R., Kimby E., Gribben J.G., Gobbi M., Dreisbach L., Hurd D.D., Sekeres M.A., Ferrajoli A., Shah S., Zhang J., Moutouh-De Parseval L., Hallek M., Heerema N.A., Stilgenbauer S., Chanan-Khan A.A.. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma. March 2012. DOI: 10.3109/10428194.2011.618232.

Impacto: 2.301. Cuartil: Q3

Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S., Iglesias M., Salido M., Gallen M., Marsters S., Tsai S.P., Minoche A., Somasekar S., Serrano S., Himmelbauer H., Bellmunt J., Rovira A., Settleman J., Bosch F., Albanell J.. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine. February 2012. DOI: 10.1038/nm.2609.

Impacto: 24.302. Cuartil: Q1 (1er decil)

Sanchez-Dominguez R., Pereira-Mendez S., Gomez A., Torrabadella M., Azqueta C., Querol S., Barquinero J., Gimeno R.. Notch signals contribute to preserve the multipotentiality of human CD34+CD38-CD45RA-CD90+ hematopoietic progenitors by maintaining T cell lineage differentiation potential. Experimental Hematology. December 2012. DOI: 10.1016/j.exphem.2012.08.009.

Impacto: 2.907. Cuartil: Q2

Calpe E., Codony C., Baptista M.J., Abrisqueta P., Carpio C., Purroy N., Bosch F., Crespo M.. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood. 20 October 2011. DOI: 10.1182/blood-2011-01-333682.

Impacto: 9.898. Cuartil: Q1 (1er decil)